Floatz logo

rd13-02 cell infusion

Hematologic Neoplasms

Kai Lin Xu，MDCell therapyEarly Phase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

136 Active assets in the Hematologic Neoplasms cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

rd13-02 cell infusion is also rated in:

hematologic disorderDormant
CC
Indicative ·
47 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
lymphoid neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →